Study identifies risk factors for ocular complications in lung cancer treatment
Patients with lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy who have certain risk factors are more likely to develop moderate to severe ocular surface disease (OSD), according to a study.
The study analyzed records from over 31,000 patients with lung cancer treated.
Among more than 6,600 patients who received EGFR-TKI therapy, 3.3% developed significant OSD, including severe conjunctivitis, keratitis, or corneal complications requiring surgery.
Higher risk was linked to female sex, older age, a history of ocular surgery, autoimmune or thyroid disease, peptic ulcers, and systemic steroid use. More severe eye complications were associated with distant cancer metastases, prior radiation therapy, and higher comorbidity burden.
Reference
Tsao YT, Kang EY, Wu CE, et al. Risk of Moderate to Severe Ocular Surface Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A Multicenter Cohort Study. Ophthalmol Ther. 2025 Jul 17. doi: 10.1007/s40123-025-01200-4. Epub ahead of print. PMID: 40676408.
Related Content
